A P PHARMA INC has a total of 46 patent applications. Its first patent ever was published in 2001. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, macromolecular chemistry and polymers and organic fine chemistry are NANOCARRIER CO LTD, NANO CAREER KK and POLYACTIVA PTY LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 15 | |
#2 | WIPO (World Intellectual Property Organization) | 9 | |
#3 | Australia | 8 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | China | 3 | |
#6 | Canada | 2 | |
#7 | Brazil | 1 | |
#8 | Israel | 1 | |
#9 | Republic of Korea | 1 | |
#10 | Mexico | 1 | |
#11 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Macromolecular chemistry and polymers | |
#3 | Organic fine chemistry | |
#4 | Machines | |
#5 | Medical technology |
# | Name | Total Patents |
---|---|---|
#1 | Heller Jorge | 27 |
#2 | Ng Steven Y | 19 |
#3 | Barr John | 9 |
#4 | Shah Devang T | 7 |
#5 | Morgan April J | 4 |
#6 | Frisbee A Roger | 4 |
#7 | Itov Zinovy | 4 |
#8 | Shen Hui-Rong | 4 |
#9 | Newsome Peter W | 4 |
#10 | Noe Robert A | 4 |
Publication | Filing date | Title |
---|---|---|
EP2370064A1 | Methods for enhancing stability of polyorthoesters and their formulations | |
WO2007133752A2 | Formulations of 5-ht3 receptor antagonists with polyorthoester for use in the prevention of acute and delayed chemotherapy- induced nausea and vomiting (cinv) | |
AU2006230226A1 | PEG-poly(ortho ester) graft copolymers and pharmaceutical compositions | |
US2005042194A1 | Semi-solid delivery vehicle and pharmaceutical compositions | |
US6863782B2 | Method of preparing di(ketene acetals) | |
US7045589B2 | Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them | |
WO02092655A1 | Bioerodible poly(orthoesters) containing hydrogen bonding groups | |
US6613355B2 | Semi-solid delivery vehicle and pharmaceutical compositions | |
US6670335B2 | Fluorouracil-containing formulation |